NASDAQ: COYACoya Therapeutics Inc Stock
$4.89+0.15 (+3.16%)
Updated Jun 15, 2026
COYA Price
$4.89
Fair Value Price
-$0.45
Market Cap
$114.71M
52 Week Low
$3.71
52 Week High
$7.75
P/E
-4.25x
P/B
2.34x
P/S
11.24x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.94M
Earnings
-$21.13M
Gross Margin
100%
Operating Margin
-266.07%
Profit Margin
-266.1%
Debt to Equity
0.09
Operating Cash Flow
-$14M
Beta
1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
COYA Overview
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine COYA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
COYA
Ranked#265 of 462
Ranked#265 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.59 | A | |
| $53.00 | A | |
| $16.00 | A |
Be the first to know about important COYA news, forecast changes, insider trades & much more!
COYA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how COYA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
COYA ($4.89) is overvalued by 1,178.5% relative to our estimate of its Fair Value price of -$0.45 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
COYA ($4.89) is not significantly undervalued (1,178.5%) relative to our estimate of its Fair Value price of -$0.45 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
COYA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more COYA due diligence checks available for Premium users.
Valuation
COYA fair value
Fair Value of COYA stock based on Discounted Cash Flow (DCF)
Price
$4.89
Fair Value
-$0.45
Undervalued by
1,178.50%
COYA ($4.89) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
COYA ($4.89) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
COYA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
COYA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.25x
Industry
16.41x
Market
14.3x
COYA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.34x
Industry
4.89x
COYA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
COYA's financial health
Profit margin
Revenue
$251.1k
Net Income
-$7.2M
Profit Margin
-2,869.6%
COYA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
COYA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$53.3M
Liabilities
$4.3M
Debt to equity
0.09
COYA's short-term assets ($53.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
COYA's short-term assets ($53.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
COYA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.2M
Investing
-$885.0k
Financing
$11.0M
COYA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
COYA vs Biotech Stocks
Coya Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.